The neurodegeneration marker appears to track disease severity in AD and MS patients with great sensitivity.
In people with ALS, researchers identified 39 new genetic variations in RNA-binding proteins that may influence the disease. Such information could inform future pharmacogenomics treatment.
New fluorescent tracers reveal cerebrospinal fluid leaving the skull through lymph vessels that run close to cranial nerve sheaths. This slows with age.
The philanthropist today announced a $50 million investment in the U.K.’s Dementia Discovery Fund, which supports startups developing innovative treatments.
Wild-type mice exposed to blood from Alzheimer’s amyloidosis mice developed plaques, tau phosphorylation, neuroinflammation, and synaptic deficits.
Signals from neuron EphB1 receptors boost neuroprotective functions in astrocytes. This line of communication appears cut in ALS.
Expressed in the brains of mice, a secreted form of the anti-aging protein, klotho, protects from an age-related decline in memory.
Tau fibrils isolated from people with AD, PSP, and CBD recapitulated the typical pathology of each disease in animals without human transgene expression.
Souvenaid missed its primary cognitive endpoint in the two-year trial, but reduced brain atrophy and slowed functional decline.
The agency’s request for information seeks feedback on the nature and value of the prize. Help shape it!
A longitudinal study identified regions in the default mode network as among the first to accumulate Aβ.
A crystal structure of the kinase bound to its substrate ubiquitin reveals role of unique PINK1 domains in phosphorylation and explains why certain mutations cause Parkinsonism.
Neuronal plasticity falters with Alzheimer’s disease, but noninvasive stimulation strengthens it. Meanwhile, mini-jolts inside the brain improve face recognition in epilepsy patients.
Participants in the A4 prevention trial wanted to know the extent of their amyloid burdens and how that affected their risk for AD. Researchers need to carefully communicate the limitations of amyloid PET.
The scheme catches earlier cases of Aβ accumulation than do global amyloid PET measures with binary positivity thresholds. And: the neuropathologists were right.
No filters selected